Ohad Hammer

Licensing Deal Is Imminent for ArQule

Thanks Basel Expat.

EXEL looks great at the current price. Similar to the overall market, all bad news (cash burn) are factored in and when multiple licensing deals are signed, I see it going substantially higher. It is less risky than ARQL, no doubt, thanks to its broad portfolio, and this should be ARQL's model as well.

EXEL just got involved in another crowded "next big thing" area yesterday, Hsp90 inhibitors. In this case it is lagging behind BMS
and SNTA among others.

Ohad

Licensing Deal Is Imminent for ArQule

Thanks

I Don't follow ARIA too closely.